Related references
Note: Only part of the references are listed.Pharmacokinetics, Mass Balance, and Metabolism of the Novel Urate Transporter 1 Inhibitor [14C]HR011303 in Humans: Metabolism Is Mediated Predominantly by UDP-Glucuronosyltransferase
Yuandong Zheng et al.
DRUG METABOLISM AND DISPOSITION (2022)
Pharmacokinetics, mass balance, and metabolism of [14C]vicagrel, a novel irreversible P2Y12 inhibitor in humans
Yuan-dong Zheng et al.
ACTA PHARMACOLOGICA SINICA (2021)
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TPN171H, a Novel Phosphodiesterase Type 5 Inhibitor, in Healthy Subjects
Hongjie Qian et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2021)
Combined Methods (Formal Adjusted Indirect Comparison, Meta-Analysis and Principal Component Analysis) Comparisons of the Safety and Efficacy of Ambrisentan, Bosentan, and Sildenafil in the Patients With Pulmonary Arterial Hypertension
Xinmei Li et al.
FRONTIERS IN PHARMACOLOGY (2020)
Pharmacokinetics-Driven Optimization of 4(3H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension
Zhen Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Characterization of TPN171 metabolism in humans via ultra-performance liquid chromatography/quadrupole time-of-flight Checir for mass spectrometry
Lulu Pan et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2019)
Pharmacokinetics, Metabolism, and Excretion of [14C] Esaxerenone, a Novel Mineralocorticoid Receptor Blocker in Humans
Makiko Yamada et al.
DRUG METABOLISM AND DISPOSITION (2019)
A Decade in the MIST: Learnings from Investigations of Drug Metabolites in Drug Development under the Metabolites in Safety Testing Regulatory Guidance
Simone Schadt et al.
DRUG METABOLISM AND DISPOSITION (2018)
Deficiency of N-acetyltransferase increases the interactions of isoniazid with endobiotics in mouse liver
Pengcheng Wang et al.
BIOCHEMICAL PHARMACOLOGY (2017)
Comparison of the inhibitory effects of tolcapone and entacapone against human UDP-glucuronosyltransferases
Xia Lv et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2016)
Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters
Lydia M. M. Vermeer et al.
DRUG METABOLISM AND DISPOSITION (2016)
Advances in targeting cyclic nucleotide phosphodiesterases
Donald H. Maurice et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Expression of Hepatic Drug-Metabolizing Cytochrome P450 Enzymes and Their Intercorrelations: A Meta-Analysis
Brahim Achour et al.
DRUG METABOLISM AND DISPOSITION (2014)
The UDP-glucuronosyltransferases: Their role in drug metabolism and detoxification
Andrew Rowland et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2013)
Pulmonary Arterial Hypertension: Challenges in Translational Research and a Vision for Change
Gopinath Sutendra et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Radiolabeled Absorption, Distribution, Metabolism, and Excretion Studies in Drug Development: Why, When, and How?
Natalia Penner et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2012)
Recent advances and future perspectives in therapeutic strategies for pulmonary arterial hypertension
Atsushi Yao
JOURNAL OF CARDIOLOGY (2012)
Characterization of Niflumic Acid as a Selective Inhibitor of Human Liver Microsomal UDP-Glucuronosyltransferase 1A9: Application to the Reaction Phenotyping of Acetaminophen Glucuronidation
John O. Miners et al.
DRUG METABOLISM AND DISPOSITION (2011)
Comparative metabolism of sildenafil in liver microsomes of different species by using LC/MS-based multivariate analysis
Sang Kyu Lee et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2011)
Simultaneous Absolute Quantification of 11 Cytochrome P450 Isoforms in Human Liver Microsomes by Liquid Chromatography Tandem Mass Spectrometry with In Silico Target Peptide Selection
Hirotaka Kawakami et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2011)
Mechanisms of disease: pulmonary arterial hypertension
Ralph T. Schermuly et al.
NATURE REVIEWS CARDIOLOGY (2011)
N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases
Sanna Kaivosaari et al.
XENOBIOTICA (2011)
2-Phenylquinazolin-4(3H)-one, a class of potent PDE5 inhibitors with high selectivity versus PDE6
Hongliang Duan et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Metabolites in safety testing
Timothy W. Robison et al.
BIOANALYSIS (2009)
The cancer paradigm of severe pulmonary arterial hypertension
Pradeep R. Rai et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines
Akiko Nakamura et al.
DRUG METABOLISM AND DISPOSITION (2008)
Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans
Stella H. Vincent et al.
DRUG METABOLISM AND DISPOSITION (2007)
Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond
Hossein A. Ghofrani et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes
Masuhiro Nishimura et al.
DRUG METABOLISM AND PHARMACOKINETICS (2006)
Potency, selectivity, and consequences of nonselectivity of PDE inhibition
E Bischoff
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH (2004)
The discovery of tadalafil:: A novel and highly selective PDE5 inhibitor.: 2:: 2,3,6,7,12,12a-hexahydropyrazino[1′,2′:1,6]pyrido[3,4-b]indole-1,4-dione analogues
A Daugan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Share Paper
